

## nrf2 Expressed by Bone

Eiichi Hinoi, Liyang Wang, Sayumi Fujimori and Yukio Yoneda\*

Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School of Natural Science and Technology, Kanazawa, Ishikawa 920-1192, Japan

**Abstract:** Nuclear factor E2-related factor 2 (nrf2) is accepted as an important transcription factor in the regulation of many phase II detoxifying enzymes and oxidative-stress-inducible genes in many tissues including bone and cartilage. However, little attention has been paid to precise role of nrf2 on osteoblasts and chondrocytes. In the present study, we therefore investigated the role of nrf2 in the regulation of cell proliferation, differentiation and maturation using both MC3T3-E1 and ATDC5 cells. In MC3T3-E1 cells stably transfected with nrf2 (MC3T3-E1-nrf2 clone), the differentiation-dependent induction of alkaline phosphatase activity was significantly inhibited in addition to decrease of the mineralized matrix formation. Moreover, expression of mRNAs for osteocalcin and type I collagen was also markedly attenuated in MC3T3E1-nrf2 clone but not in MC3T3E1-empty vector clone. These inhibitory effect on cell differentiation was also observed in ATDC5 cells stably transfected with nrf2. Moreover, nrf2 significantly impaired the runx2-dependent enhancement of osteocalcin promoter activity. These data suggest that nrf2 may negatively regulate the differentiation of both osteoblasts and chondrocytes through inhibition of the runx2 dependent transcriptional activity.

**Key words:** osteoblasts, chondrocytes, transcription factors, nrf2, runx2

### Introduction

In bone tissues, two distinct cell types are known to sophisticatedly regulate bone formation and maintenance<sup>1,2</sup>. These are bone-forming osteoblasts and bone-resorbing osteoclasts. The osteoblast lineage is derived from primitive multipotent mesenchymal stem cells with potentiality to differentiate into bone marrow stromal cells, chondrocytes, muscles and adipocytes<sup>3</sup>, while osteoclasts are multinucleated cells derived from the fusion of mononuclear hematopoietic precursors<sup>4</sup>. The development and differentiation of these two distinct cells are under the tight regulation by a number of transcription factors. Among them, Runx2, a cell-specific member of the Runt family of transcription factors, play a pivotal role in osteoblastic differentiation. Runx2 is the earliest and most specific molecular marker of the osteoblast lineage, its expression is both necessary and sufficient to induce osteoblast differentiation, and it regulates expression of most genes characteristic of the osteoblast phenotype<sup>5,6,7</sup>. Runx2 is also required for chondrocyte hypertrophy in bones ossifying through endochondral ossification<sup>8</sup>.

Transcription factor nuclear factor E2-related factor 2 (nrf2) belongs to the cap-n-collar family of activators that shares a highly conserved basic region-leucine zipper structure<sup>9</sup>. Nrf2 forms heterodimers with the small Maf proteins, and binds to the antioxidant responsive element or electrophile responsive elements of target genes, followed by regulation of many phase II detoxifying enzymes and oxidative-stress-inducible genes in many tissues including bone and cartilage<sup>10,11</sup>. However, little attention has been paid to precise role of nrf2 on osteoblasts and chondrocytes. In the present study, we therefore investigated the role of nrf2 in the regulation of cell proliferation, differentiation and maturation using both MC3T3-E1 and ATDC5 cells.

### Materials and Methods

Correspondence to Dr. Yukio Yoneda, Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School of Natural Science and Technology, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan, Tel/Fax: 81-(0)76-234-4471E-mail: yyoneda@anet.ne.jp

### *In situ hybridization analysis*

Sections mounted were fixed with 4% paraformaldehyde, followed by treating with 0.2 M HCl and subsequent treating with 10 mg/mL Proteinase K. Sections were then subjected to acetylation in 0.1 M triethanolamine/0.25% acetic anhydride and subsequent stepwise dehydration in 70, 80, 90, 95 and 100 % ethanol. After being dried, sections were covered with digoxigenin (DIG)-labeled cRNA probes at 65°C for 16 h. Post-hybridization washes were done stepwise with 4XSSC at 65°C, 50% formamide in 2XSSC at 65°C, 4 mg/mL RNase A at 37°C, 2XSSC at 65°C, 0.2XSSC at 65°C, and then 1.5% blocking buffer. Subsequently, sections were incubated with anti-DIG-AP antibody at 4°C for 16 h, followed by treating with NBT/BCIP for different periods.

### *Stable transfection*

MC3T3-E1 and ATDC5 cells were plated at a density of 1.5 x 10<sup>5</sup> cells/cm<sup>2</sup>. After 24 h, they were stably transfected with pEF containing the full-length coding region of nrf2 (MC3T3-E1-nrf2 and ATDC5-nrf2) or with the empty vector (MC3T3-E1-EV and ATDC5-EV) using 2 µg of DNA and Lipofectamine and Plus reagent (Invitrogen, Carlsbad, CA) in 10 ml of medium. After 24 h, and every 48 h thereafter for 2 weeks, media were replaced with fresh media containing 600 µg/ml of G418. This dose and duration of treatment resulted in the death of all nontransfected cells within 10 days. Pools of 10 clones of MC3T3-E1-nrf2 and ATDC5-nrf2 were isolated for further studies. Pools of clones between passages 2 and 5 were used for the experiments reported.

### *Constructs and Luciferase Assay*

A full-length mouse osteocalcin promoter with luciferase as the reporter gene (OG2) was generously gift from Dr. Karsenty. OG2 reporter was co-transfected with TK-*Renilla* luciferase construct in either the presence or absence of nrf2 and/or runx2 expression vector into MC3T3-E1 cells and COS7 cells. Two days after transfection, cells were lysed, and luciferase activity was determined using specific substrates in a luminometer according to the manufacturer's protocol (Promega Madison, MI). Transfection efficiency was normalized by determining the activity

of *Renilla luciferase*.

#### Data analysis

Results are all expressed as the mean±S.E. and the statistical significance was determined by the two-tailed and unpaired Students' *t*-test or the one-way analysis of variance ANOVA with Bonferroni/Dunnett post hoc test.

### Results

#### Expression of *nrf2* in bone and cartilage

In order to at first evaluate the possible expression of *nrf2* in bone and cartilage, *in situ* hybridization was conducted on sections dissected from neonatal mouse tibia. type I collagen was specifically expressed by osteoblasts without any layers of differentiating chondrocytes. In addition, type II collagen was preferentially expressed by proliferating to prehypertrophic chondrocytes and type X collagen was highly expressed by hypertrophic chondrocytes. Under the experimental conditions used here, *nrf2* was expressed in osteoblasts on trabecular bone as well as all chondrocyte layers.

#### Expression of *nrf2* in MC3T3-E1 cells

To examine whether *nrf2*/Maf signaling molecules are indeed expressed in MC3T3-E1 osteoblastic cells, RT-PCR analysis was conducted. Semi-quantitative RT-PCR revealed that expression of mRNA was drastically increased for osteocalcin during culturing from 14 days with a gradual increase thereafter up to 28 days, while a sustained expression was seen in mRNA expression for both type I collagen and *runx2* for a period up to 28 days. Under these conditions, Expression of mRNA for *nrf2* was gradually increased 3 to 14 days, while no marked alteration was found in Keap1, MafF and MafG mRNA expression at any stages examined.

#### Effect of *nrf2* on osteoblastic differentiation

To assess whether stable expression of *nrf2* could alter the program of osteoblastic differentiation, MC3T3-E1 and ATDC5 cells were stably transfected with pEF containing the full-length coding region of *nrf2* (MC3T3-E1-*nrf2* and ATDC5-*nrf2*) or with the empty vector (MC3T3-E1-EV and ATDC5-*nrf2*). In MC3T3-E1-*nrf2* cells, marked decrease was found in alkaline phosphatase activity as well as the expression of type I collagen and osteocalcin when compared with MC3T3-E1-EV cells. In addition, intensity of alizarin red staining and Ca<sup>2+</sup> accumulation were also significantly decreased in MC3T3-E1-*nrf2* cells.

#### Effect of *nrf2* on *runx2*-dependent OG2 reporter activity

An attempt was next made to determine the possible mechanisms of *nrf2* on osteoblastic differentiation by determination of reporter activity using mouse osteocalcin promoter, OG2. OG2 reporter activity was significantly enhanced by *runx2* expression as previously reported, while no marked increase was found by transfection with *nrf2* alone. In contrast, *nrf2* significantly impaired the *runx2*-dependent enhancement of OG2 reporter activity when it was simultaneously transfected with *runx2*.

### Discussion

The essential importance of the present findings is that the overexpression of *nrf2* markedly inhibited osteoblastic

differentiation. In addition, *nrf2* almost completely inhibited *runx2*-dependent osteocalcin promoter activity. To our knowledge, this paper deals with the first direct demonstration of functional expression of *nrf2* in osteoblasts. Although several previous studies have already demonstrated the functional expression of *nrf2* in bone<sup>12,13</sup>, no direct evidence for a role of it in mechanisms underlying the cellular differentiation in osteoblasts is available in the literature to date.

*Nrf2*/Maf signaling machineries could be thus a target for the development of a drug useful for the treatment and therapy of a variety of bone diseases relevant to abnormal development and maturation of osteoblasts in human beings.

### Acknowledgements

This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare, Japan.

### References

1. Boyle WJ, Simonet WS and Lacey DL. Osteoclast differentiation and activation. *Nature* 423:337-342, 2003
2. Harada S and Rodan GA. Control of osteoblast function and regulation of bone mass. *Nature* 423:349-355, 2003
3. Ducy P, Schinke T and Karsenty G The osteoblast: a sophisticated fibroblast under central surveillance. *Science* 289:1501-1504, 2000
4. Teitelbaum SL. Bone resorption by osteoclasts. *Science* 289:1504-1508, 2000
5. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR et al. *Cbfa1*, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell* 89:765-771, 1997
6. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M et al. Targeted disruption of *cbfa1* results in a complete lack of bone formation owing to maturational arrest of Osteoblasts. *Cell* 89:755-764, 1997
7. Ducy P, Zhang R, Geoffroy V, Ridall AL and Karsenty G. *Osf2/Cbfa1*: a transcriptional activator of osteoblast differentiation. *Cell* 89:747-754, 1997
8. Takeda S, Bonnamy JP, Owen MJ, Ducy P and Karsenty G. Continuous expression of *cbfa1* in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues *cbfa1*-deficient mice. *Genes Dev.* 15:467-481, 2001
9. Motohashi H and Yamamoto M. *Nrf2*-Keap1 defines a physiologically important stress response mechanism. *Trends Mol Med* 10:549-557, 2004
10. Zhang Y and Gordon GB. A strategy for cancer prevention: stimulation of the *Nrf2*-ARE signaling pathway. *Mol Cancer Ther* 3:885-893, 2004
11. Lee JS and Surh YJ. *Nrf2* as a novel molecular target for chemoprevention. *Cancer Lett* 224:171-184, 2005
12. Li B, Wang X, Rasheed N, Hu Y, Boast S, Ishii T, Nakayama K, Nakayama KI and Goff SP. Distinct roles of *c-Abl* and *Atm* in oxidative stress response are mediated by protein kinase C delta. *Genes Dev* 18:1824-1837, 2004
13. Beck GR, Moran E and Knecht N. Inorganic phosphate regulates multiple genes during osteoblast differentiation, including *Nrf2*. *Exp Cell Res* 288:288-300, 2003